LearnGlossaryMarketStocksSuperinvestorsSign in

LQDA

Liquidia Corporation

Healthcare · $6.1B market cap

Verdict

We can't put a fair value on LQDA right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-18.6% a year✗
Sales growth9.7% a year✗
Free cash flow growth—?
Return on invested capital-50.0%✗

Follow LQDA

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

None of the investors we track holds LQDA right now. In Q1 2026, 1 sold out. Who we track

Moves in Q1 2026

Sold out: Polen Capital Management

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 sale worth $19K. Why purchases matter

Sales

Krepp Sarah

Chief Human Resource Officer · 2026-09-01

Sold

$19K

About Liquidia Corporation

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its…

Medical - Pharmaceuticals

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works